1,116
Participants
Start Date
July 28, 2025
Primary Completion Date
February 21, 2030
Study Completion Date
July 29, 2032
Volrustomig
Volrustomig will be administered as an intravenous (IV) infusion.
Casdatifan
Casdatifan will be administered orally.
Nivolumab
Nivolumab will be administered as an IV infusion.
Ipilimumab
Ipilimumab will be administered as an IV infusion.
NOT_YET_RECRUITING
Research Site, Tainan City
NOT_YET_RECRUITING
Research Site, East Melbourne
NOT_YET_RECRUITING
Research Site, Syndey
NOT_YET_RECRUITING
Research Site, North Adelaide
RECRUITING
Research Site, Elizabeth Vale
NOT_YET_RECRUITING
Research Site, Seoul
NOT_YET_RECRUITING
Research Site, Nedlands
NOT_YET_RECRUITING
Research Site, Batumi
NOT_YET_RECRUITING
Research Site, New York
NOT_YET_RECRUITING
Research Site, Seongnam-si
NOT_YET_RECRUITING
Research Site, Seongnam-si
NOT_YET_RECRUITING
Research Site, Nashville
NOT_YET_RECRUITING
Research Site, Taichung
NOT_YET_RECRUITING
Research Site, Cleveland
RECRUITING
Research Site, Busan
NOT_YET_RECRUITING
Research Site, Lubbock
NOT_YET_RECRUITING
Research Site, Aurora
NOT_YET_RECRUITING
Research Site, La Jolla
NOT_YET_RECRUITING
Research Site, Beijing
NOT_YET_RECRUITING
Research Site, Shanghai
NOT_YET_RECRUITING
Research Site, Xiamen
NOT_YET_RECRUITING
Research Site, Taichung
NOT_YET_RECRUITING
Research Site, Guangzhou
NOT_YET_RECRUITING
Research Site, Nanning
NOT_YET_RECRUITING
Research Site, Kaohsiung City
NOT_YET_RECRUITING
Research Site, Nanjing
NOT_YET_RECRUITING
Research Site, Boston
NOT_YET_RECRUITING
Research Site, Tbilisi
NOT_YET_RECRUITING
Research Site, Tbilisi
NOT_YET_RECRUITING
Research Site, Tbilisi
NOT_YET_RECRUITING
Research Site, Seoul
NOT_YET_RECRUITING
Research Site, Seoul
NOT_YET_RECRUITING
Research Site, Seoul
Lead Sponsor
Collaborators (1)
Arcus Biosciences, Inc.
INDUSTRY
AstraZeneca
INDUSTRY